A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia

Haematologica. 2009 Mar;94(3):433-5. doi: 10.3324/haematol.13283. Epub 2009 Jan 30.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Amino Acid Substitution
  • Chromosomes, Human, Pair 21 / genetics
  • Chromosomes, Human, Pair 8 / genetics
  • Female
  • Humans
  • Janus Kinase 2 / genetics*
  • Kaplan-Meier Estimate
  • Leukemia, Myeloid / genetics*
  • Leukemia, Myeloid / pathology
  • Male
  • Mutation
  • Proto-Oncogene Proteins c-kit / genetics*
  • Translocation, Genetic*
  • fms-Like Tyrosine Kinase 3 / genetics*

Substances

  • FLT3 protein, human
  • Proto-Oncogene Proteins c-kit
  • fms-Like Tyrosine Kinase 3
  • Janus Kinase 2